Multivariate Cox regression analyzes for PFS of the paired-NSCLC cohort stratified by tumor purity
| Variables | Total patients (n=156) | Adequate purity (n=87) | Low purity (n=69) | ||||||||||
| Model 1 (WES-TMB) | Model 2 (panel-TMB) | Model 1 (WES-TMB) | Model 2 (panel-TMB) | Model 1 (WES-TMB) | Model 2 (panel-TMB) | ||||||||
| aHR (95% CI) | P value | aHR (95% CI) | P value | aHR (95% CI) | P value | aHR (95% CI) | P value | aHR (95% CI) | P value | aHR (95% CI) | P value | ||
| Age | (cont) | 1 (0.99 to 1.02) | 0.762 | 1 (0.98 to 1.02) | 0.923 | 0.99 (0.97 to 1.01) | 0.335 | 0.99 (0.96 to 1.01) | 0.257 | 1.01 (0.98 to 1.04) | 0.583 | 1.02 (0.99 to 1.05) | 0.313 |
| Sex | M | 1 (Reference) | – | 1 (Reference) | – | 1 (Reference) | – | 1 (Reference) | – | 1 (Reference) | – | 1 (Reference) | – |
| F | 1.07 (0.72 to 1.59) | 0.725 | 1.08 (0.73 to 1.58) | 0.705 | 1.21 (0.72 to 2.04) | 0.467 | 1.29 (0.77 to 2.15) | 0.329 | 0.88 (0.46 to 1.7) | 0.707 | 0.77 (0.40 to 1.48) | 0.436 | |
| Lines of therapy received | 0 | 1 (Reference) | – | 1 (Reference) | – | 1 (Reference) | – | 1 (Reference) | – | 1 (Reference) | – | 1 (Reference) | – |
| 1 | 1.64 (0.81 to 3.3) | 0.166 | 1.63 (0.81 to 3.28) | 0.17 | 2.04 (0.76 to 5.51) | 0.157 | 1.86 (0.7 to 4.98) | 0.214 | 1.27 (0.43 to 3.72) | 0.666 | 1.61 (0.54 to 4.80) | 0.391 | |
| 2 | 1.11 (0.53 to 2.32) | 0.777 | 1.12 (0.53 to 2.34) | 0.766 | 2.67 (0.95 to 7.53) | 0.064 | 2.78 (0.99 to 7.85) | 0.053 | 0.58 (0.19 to 1.79) | 0.345 | 0.65 (0.21 to 1.98) | 0.227 | |
| 3 | 1.37 (0.65 to 2.87) | 0.407 | 1.37 (0.65 to 2.88) | 0.408 | 1.81 (0.66 to 4.98) | 0.249 | 1.59 (0.58 to 4.36) | 0.37 | 0.94 (0.29 to 3.06) | 0.914 | 1.33 (0.40 to 4.49) | 0.641 | |
| ECOG PS | 0 | 1 (Reference) | – | 1 (Reference) | – | 1 (Reference) | – | 1 (Reference) | – | 1 (Reference) | – | 1 (Reference) | – |
| 1 | 2.22 (0.3 to 16.21) | 0.431 | 2.35 (0.32 to 17.17) | 0.399 | ND | 0.996 | ND | 0.996 | 0.41 (0.05 to 3.4) | 0.408 | 0.39 (0.05 to 3.27) | 0.383 | |
| 2 | 3.9 (0.5 to 30.58) | 0.195 | 4.18 (0.53 to 32.8) | 0.174 | ND | 0.996 | ND | 0.996 | 1.34 (0.13 to 13.39) | 0.802 | 1.15 (0.12 to 11.53) | 0.902 | |
| TMB group | Low | 1 (Reference) | – | 1 (Reference) | – | 1 (Reference) | – | 1 (Reference) | – | 1 (Reference) | – | 1 (Reference) | – |
| High |
0.59
(0.36 to 0.97) | 0.037 |
0.5
(0.3 to 0.82) | 0.006 |
0.49
(0.26 to 0.90) | 0.022 |
0.46
(0.24 to 0.89) | 0.02 |
0.54
(0.21 to 1.41) | 0.212 |
0.32
(0.13 to 0.82) | 0.016 | |
aHR, adjusted HR; ECOG, Eastern Cooperative Oncology Group; ND, not determined; NSCLC, non-small-cell lung cancer; PFS, progression-free survival; PS, performance status; TMB, tumor mutational burden; WES, whole-exome sequencing.